^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    177Lu-DTPA-omburtamab

    Associations

    News

    Trials
    Company:
    Y-mAbs Therap
    Drug class:
    Ionizing radiation emitter, B7-H3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4years
    177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma (clinicaltrialsregister.eu)
    P1/2, N=49, Y-mAbs Therapeutics, Inc.
    Clinical • New P1/2 trial
    |
    CD276 (CD276 Molecule)
    |
    177Lu-DTPA-omburtamab